Skip to main content
Erschienen in: Indian Journal of Pediatrics 6/2024

29.06.2023 | Original Article

Treatment of Pediatric Acute Promyelocytic Leukemia with Retinoic Acid and Arsenic Trioxide along with Chemotherapy

verfasst von: Shyam Srinivasan, Chetan Dhamne, Nirmalya Roy Moulik, Akanksha Chichra, Prashant Tembhare, Nikhil Patkar, P. G. Subramanian, Dhanlaxmi Shetty, Gaurav Narula, Shripad Banavali

Erschienen in: Indian Journal of Pediatrics | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Outcomes of childhood acute promyelocytic leukemia (APL) have exceeded 90% in the era of differentiating agents. In resource-limited settings, early mortality secondary to coagulopathy remains a significant challenge. Differentiation syndrome is a unique complication of APL therapy that requires a high degree of suspicion for timely initiation of therapy.

Methods

A retrospective study of children ≤15 y of age with APL diagnosed between January-2013 and June-2019 treated at a tertiary cancer centre was conducted. Patients with a total leukocyte count ≥10,000/µL were risk stratified as high-risk. Treatment included differentiating agents, all-trans retinoic acid and arsenic trioxide along with chemotherapy. Baseline demographics, clinical complications and outcomes were analysed.

Results

Out of 90 patients treated, 48 (53%) had high-risk APL and 25 (28%) presented with significant bleeding manifestations. Response to therapy was excellent with 96% of evaluable patients achieving molecular remission by the end of consolidation phase. Differentiation syndrome occurred in 23 (25%) patients of which two expired. Early mortality rate was 5.5% and was due to severe hemorrhage most often at the time of presentation. The 3-y overall survival of the entire cohort was 91% (95% CI: 85–97%). Two of 4 patients with relapse of disease could be salvaged with only differentiating agents followed by autologous transplantation.

Conclusions

Long-term outcomes of Indian children with APL are excellent. Timely management of coagulopathy and prompt initiation of differentiating agents along with appropriate cytoreductive measures is critical. Efforts to build academic-community partnerships to ensure timely diagnosis and emergency care in order to reduce early mortality are needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–15.CrossRefPubMed Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–15.CrossRefPubMed
2.
Zurück zum Zitat Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21.CrossRefPubMed Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21.CrossRefPubMed
3.
Zurück zum Zitat Micol JB, Raffoux E, Boissel N, et al. Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. Eur J Cancer. 2014;50:1159–68.CrossRefPubMed Micol JB, Raffoux E, Boissel N, et al. Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. Eur J Cancer. 2014;50:1159–68.CrossRefPubMed
4.
Zurück zum Zitat Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018;32:89–95.CrossRefPubMed Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018;32:89–95.CrossRefPubMed
5.
Zurück zum Zitat Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: Association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica. 2010;95:853–4.CrossRefPubMed Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: Association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica. 2010;95:853–4.CrossRefPubMed
6.
Zurück zum Zitat Golamari K, Mikkilineni A, Chappidi S. Early death in acute promyelocytic leukemia: evidence from a rural cancer center. Indian J Cancer. 2020;57:451–6.CrossRefPubMed Golamari K, Mikkilineni A, Chappidi S. Early death in acute promyelocytic leukemia: evidence from a rural cancer center. Indian J Cancer. 2020;57:451–6.CrossRefPubMed
7.
Zurück zum Zitat Serefhanoglu S, Buyukasik Y, Goker H, et al. Clinical features and outcomes of 49 turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res. 2010;34:e317–9.CrossRefPubMed Serefhanoglu S, Buyukasik Y, Goker H, et al. Clinical features and outcomes of 49 turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy. Leuk Res. 2010;34:e317–9.CrossRefPubMed
8.
Zurück zum Zitat Abla O, Ribeiro RC. How I treat children and adolescents with acute promyelocytic leukaemia. Br J Haematol. 2014;164:24–38.CrossRefPubMed Abla O, Ribeiro RC. How I treat children and adolescents with acute promyelocytic leukaemia. Br J Haematol. 2014;164:24–38.CrossRefPubMed
9.
Zurück zum Zitat Banavali SD, Goyal L, Nair R, et al. A novel, efficacious therapeutic approach to patients with acute promyelocytic leukemia (APL) using differentiating agent and metronomic chemotherapy (CT). Blood. 2005;106:900.CrossRef Banavali SD, Goyal L, Nair R, et al. A novel, efficacious therapeutic approach to patients with acute promyelocytic leukemia (APL) using differentiating agent and metronomic chemotherapy (CT). Blood. 2005;106:900.CrossRef
10.
Zurück zum Zitat Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 2001;97:3919–24.CrossRefPubMed Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 2001;97:3919–24.CrossRefPubMed
11.
Zurück zum Zitat Xie BS, Zhao HC, Yao SK, et al. Autophagy inhibition enhances etoposide-induced cell death in human hepatoma G2 cells. Int J Mol Med. 2011;27:599–606.PubMed Xie BS, Zhao HC, Yao SK, et al. Autophagy inhibition enhances etoposide-induced cell death in human hepatoma G2 cells. Int J Mol Med. 2011;27:599–606.PubMed
12.
Zurück zum Zitat Kutny MA, Alonzo TA, Abla O, et al. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the children’s Oncology Group AAML1331 Trial. JAMA Oncol. 2022;8:79–87.CrossRefPubMed Kutny MA, Alonzo TA, Abla O, et al. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the children’s Oncology Group AAML1331 Trial. JAMA Oncol. 2022;8:79–87.CrossRefPubMed
13.
Zurück zum Zitat Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295–305.CrossRefPubMed Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295–305.CrossRefPubMed
14.
Zurück zum Zitat Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018;132:405–12.CrossRefPubMed Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018;132:405–12.CrossRefPubMed
15.
Zurück zum Zitat Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106:447–53.CrossRefPubMed Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106:447–53.CrossRefPubMed
16.
Zurück zum Zitat Zhang Y, Wang L, Zhang R, et al. Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children’s Hospital APL 2005 protocol (BCH-APL 2005). Pediatr Hematol Oncol. 2019;36:399–409.CrossRefPubMed Zhang Y, Wang L, Zhang R, et al. Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children’s Hospital APL 2005 protocol (BCH-APL 2005). Pediatr Hematol Oncol. 2019;36:399–409.CrossRefPubMed
17.
Zurück zum Zitat Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol. 2002;70:292–9.CrossRefPubMed Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol. 2002;70:292–9.CrossRefPubMed
18.
Zurück zum Zitat Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469–73.CrossRefPubMed Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469–73.CrossRefPubMed
19.
Zurück zum Zitat Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129:1275–83.CrossRefPubMedPubMedCentral Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129:1275–83.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019;187:157–62.CrossRefPubMed Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019;187:157–62.CrossRefPubMed
21.
Zurück zum Zitat Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113:775–83.CrossRefPubMed Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113:775–83.CrossRefPubMed
22.
Zurück zum Zitat Kutny MA, Alonzo TA, Gerbing RB, et al. Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the children’s Oncology Group phase III historically controlled trial AAML0631. J Clin Oncol. 2017;35:3021–9.CrossRefPubMedPubMedCentral Kutny MA, Alonzo TA, Gerbing RB, et al. Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia: report from the children’s Oncology Group phase III historically controlled trial AAML0631. J Clin Oncol. 2017;35:3021–9.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Bajpai J, Sharma A, Kumar L, et al. Acute promyelocytic leukemia: an experience from a tertiary care centre in north India. Indian J Cancer. 2011;48:316–22.CrossRefPubMed Bajpai J, Sharma A, Kumar L, et al. Acute promyelocytic leukemia: an experience from a tertiary care centre in north India. Indian J Cancer. 2011;48:316–22.CrossRefPubMed
24.
Zurück zum Zitat Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–32.CrossRefPubMed Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–32.CrossRefPubMed
25.
Zurück zum Zitat Roy PS, Munikoty V, Trehan A, et al. Early mortality continues to be a barrier to excellent survival in childhood acute promyelocytic leukemia: a retrospective study of 62 patients spanning 17 years. Pediatr Hematol Oncol. 2023;40:117–30.CrossRefPubMed Roy PS, Munikoty V, Trehan A, et al. Early mortality continues to be a barrier to excellent survival in childhood acute promyelocytic leukemia: a retrospective study of 62 patients spanning 17 years. Pediatr Hematol Oncol. 2023;40:117–30.CrossRefPubMed
26.
Zurück zum Zitat Jillella AP, Arellano ML, Gaddh M, et al. Comanagement strategy between academic institutions and community practices to reduce induction mortality in acute promyelocytic leukemia. JCO Oncol Pract. 2021;17:e497–505.CrossRefPubMed Jillella AP, Arellano ML, Gaddh M, et al. Comanagement strategy between academic institutions and community practices to reduce induction mortality in acute promyelocytic leukemia. JCO Oncol Pract. 2021;17:e497–505.CrossRefPubMed
27.
Zurück zum Zitat Jatia S, Prasad M, Paradkar A, et al. Holistic support coupled with prospective tracking reduces abandonment in childhood cancers: a report from India. Pediatr Blood Cancer. 2019;66:e27716.CrossRefPubMed Jatia S, Prasad M, Paradkar A, et al. Holistic support coupled with prospective tracking reduces abandonment in childhood cancers: a report from India. Pediatr Blood Cancer. 2019;66:e27716.CrossRefPubMed
Metadaten
Titel
Treatment of Pediatric Acute Promyelocytic Leukemia with Retinoic Acid and Arsenic Trioxide along with Chemotherapy
verfasst von
Shyam Srinivasan
Chetan Dhamne
Nirmalya Roy Moulik
Akanksha Chichra
Prashant Tembhare
Nikhil Patkar
P. G. Subramanian
Dhanlaxmi Shetty
Gaurav Narula
Shripad Banavali
Publikationsdatum
29.06.2023
Verlag
Springer India
Erschienen in
Indian Journal of Pediatrics / Ausgabe 6/2024
Print ISSN: 0019-5456
Elektronische ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-023-04689-4

Weitere Artikel der Ausgabe 6/2024

Indian Journal of Pediatrics 6/2024 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.